122 results about "Granuloma" patented technology

Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.

Humanized antibodies specifically binding to hTNF-a are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the origninal mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-a-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.

The invention discloses an external medicament for treating bacterial vaginosis and colpitis mycotica. The external medicament is a medicament prepared from Chinese medicinal raw materials including 35-70 parts by weight of amur corktree bark, 30-60 parts by weight of lightyellow sophora root, 30-60 parts by weight of cortex ailanthi, 20-40 parts by weight of polygonum aviculare, 10-35 parts by weight of selinum japenious seed and 1-2.5 parts by weight of borneol according to the conventional preparation method. As proved by a pharmacodynamic test, the medicament has a remarkable in-vitro antibacterial action, and can be used for effectively killing and suppressing common pathogenic bacteria of reproductive tract infection; the medicament has a remarkable treatment effect on rabbit colpitis mycotica; compared with a model control group, a medicament group has the advantages: the vagina cleanliness and curative ratio are increased remarkably, and the pathological feature of rabbit colpitis mycotica can be improved remarkably; the medicament has a remarkable anti-inflammatory effect, and can be used for remarkably relieving dimethyl benzene-caused mouse auricle inflammation, suppressing the formation of mouse granuloma and reducing the mouse abdominal cavity capillary permeability; and the medicament has a certain itching relieving effect.